The CDC was ordered to shelve promotions it developed for a variety of vaccines after Health Secretary RFK Jr. said he wants ...
The Pennsylvania Supreme Court denied defendants' petition for allowance of appeal in Syngenta Crop Protection v. Nemeth, leaving unresolved the lingering uncertainty that has followed the U.S.
Express consent means that federally regulated financial institutions must get your permission before providing financial products or services to you. This applies to all products and services such as ...
The hope is that these investments lead to products like Johnson & Johnson’s Spravato, a form of ketamine used in treatment-resistant depression as well as certain cases of major depression. Sales ...
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the immediate impact Spravato has had on patients with treatment-resistant ...
An estimated 21 million American adults suffer from clinical depression. © 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...
Wells Fargo WFC-1.95%decrease; red down pointing triangle said Tuesday that its 2022 consent order with the Consumer Financial Protection Bureau relating to auto lending, consumer deposit accounts ...
Eli Lilly is discontinuing a Phase 2 relaxin treatment candidate for heart failure and chronic kidney disease, a spokesperson for the company confirmed to … ...
Mr Arora was charged with three counts of intentionally record intimate image without consent and three counts of behave in offensive manner in/near public place/school. Police escort Kamal Arora ...
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the approval of Spravato for treatment-resistant depression. PE: How does ...
The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results